The in vivo properties of a series of 2-arylindole NK1 antagonists have bee
n improved, by modification of the amide substituent. The 1-(2-methoxypheny
l)piperazine amide was identified as a major area of metabolism in the lead
compound 1. Replacement of this amine moiety by a 4-benzyl-4-hydroxypiperi
dine resulted in a compound IS with reduced clearance and improved central
duration of action. (C) 2001 Published by Elsevier Science Ltd.